vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and RE/MAX Holdings, Inc. (RMAX). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $71.1M, roughly 1.7× RE/MAX Holdings, Inc.). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs 2.0%, a 1.3% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs -1.8%). RE/MAX Holdings, Inc. produced more free cash flow last quarter ($33.5M vs $7.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs -4.7%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
RE/MAX is an international real estate franchise operating in over 100 countries and territories that, in 2015, had over 100,000 agents in 6,800 offices.
NATR vs RMAX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $71.1M |
| Net Profit | $4.1M | $1.4M |
| Gross Margin | 72.5% | — |
| Operating Margin | 4.3% | 13.1% |
| Net Margin | 3.3% | 2.0% |
| Revenue YoY | 4.7% | -1.8% |
| Net Profit YoY | 1379.4% | -75.2% |
| EPS (diluted) | $0.23 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $71.1M | ||
| Q3 25 | $128.3M | $73.2M | ||
| Q2 25 | $114.8M | $72.8M | ||
| Q1 25 | $113.2M | $74.5M | ||
| Q4 24 | $118.2M | $72.5M | ||
| Q3 24 | $114.6M | $78.5M | ||
| Q2 24 | $110.6M | $78.5M | ||
| Q1 24 | $111.0M | $78.3M |
| Q4 25 | $4.1M | $1.4M | ||
| Q3 25 | $5.3M | $4.0M | ||
| Q2 25 | $5.3M | $4.7M | ||
| Q1 25 | $4.7M | $-2.0M | ||
| Q4 24 | $-321.0K | $5.8M | ||
| Q3 24 | $4.3M | $966.0K | ||
| Q2 24 | $1.3M | $3.7M | ||
| Q1 24 | $2.3M | $-3.4M |
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 71.4% | — | ||
| Q1 24 | 71.2% | — |
| Q4 25 | 4.3% | 13.1% | ||
| Q3 25 | 7.0% | 25.0% | ||
| Q2 25 | 3.7% | 19.3% | ||
| Q1 25 | 5.4% | 7.2% | ||
| Q4 24 | 3.8% | 5.9% | ||
| Q3 24 | 4.6% | 19.4% | ||
| Q2 24 | 5.1% | 20.6% | ||
| Q1 24 | 4.2% | 5.8% |
| Q4 25 | 3.3% | 2.0% | ||
| Q3 25 | 4.2% | 5.4% | ||
| Q2 25 | 4.6% | 6.4% | ||
| Q1 25 | 4.2% | -2.6% | ||
| Q4 24 | -0.3% | 8.0% | ||
| Q3 24 | 3.8% | 1.2% | ||
| Q2 24 | 1.2% | 4.7% | ||
| Q1 24 | 2.1% | -4.3% |
| Q4 25 | $0.23 | — | ||
| Q3 25 | $0.30 | — | ||
| Q2 25 | $0.28 | — | ||
| Q1 25 | $0.25 | — | ||
| Q4 24 | $-0.02 | — | ||
| Q3 24 | $0.23 | — | ||
| Q2 24 | $0.07 | — | ||
| Q1 24 | $0.12 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $118.7M |
| Total DebtLower is stronger | — | $432.2M |
| Stockholders' EquityBook value | $161.6M | $452.4M |
| Total Assets | $261.1M | $582.5M |
| Debt / EquityLower = less leverage | — | 0.96× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.9M | $118.7M | ||
| Q3 25 | $95.6M | $107.5M | ||
| Q2 25 | $81.3M | $94.3M | ||
| Q1 25 | $86.5M | $89.1M | ||
| Q4 24 | $84.7M | $96.6M | ||
| Q3 24 | $78.7M | $83.8M | ||
| Q2 24 | $68.7M | $66.1M | ||
| Q1 24 | $77.8M | $82.1M |
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | $2.1M | $439.0M |
| Q4 25 | $161.6M | $452.4M | ||
| Q3 25 | $166.7M | $448.1M | ||
| Q2 25 | $163.7M | $442.4M | ||
| Q1 25 | $167.1M | $433.5M | ||
| Q4 24 | $161.0M | $429.5M | ||
| Q3 24 | $162.6M | $423.1M | ||
| Q2 24 | $156.4M | $418.4M | ||
| Q1 24 | $159.7M | $412.0M |
| Q4 25 | $261.1M | $582.5M | ||
| Q3 25 | $264.8M | $582.2M | ||
| Q2 25 | $254.9M | $574.8M | ||
| Q1 25 | $252.7M | $571.4M | ||
| Q4 24 | $240.9M | $581.6M | ||
| Q3 24 | $245.3M | $578.6M | ||
| Q2 24 | $235.8M | $571.4M | ||
| Q1 24 | $247.3M | $566.7M |
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | 0.01× | 1.07× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $40.9M |
| Free Cash FlowOCF − Capex | $7.6M | $33.5M |
| FCF MarginFCF / Revenue | 6.1% | 47.1% |
| Capex IntensityCapex / Revenue | 1.9% | 10.4% |
| Cash ConversionOCF / Net Profit | 2.41× | 28.39× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $56.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $40.9M | ||
| Q3 25 | $18.5M | $17.7M | ||
| Q2 25 | $4.3M | $4.6M | ||
| Q1 25 | $2.6M | $5.7M | ||
| Q4 24 | $12.2M | $59.7M | ||
| Q3 24 | $9.6M | $17.6M | ||
| Q2 24 | $1.3M | $15.9M | ||
| Q1 24 | $2.2M | $9.4M |
| Q4 25 | $7.6M | $33.5M | ||
| Q3 25 | $16.8M | $16.4M | ||
| Q2 25 | $3.0M | $2.9M | ||
| Q1 25 | $1.5M | $4.0M | ||
| Q4 24 | $10.0M | $53.0M | ||
| Q3 24 | $7.9M | $16.3M | ||
| Q2 24 | $-2.0M | $14.0M | ||
| Q1 24 | $-1.5M | $6.8M |
| Q4 25 | 6.1% | 47.1% | ||
| Q3 25 | 13.1% | 22.4% | ||
| Q2 25 | 2.6% | 4.0% | ||
| Q1 25 | 1.3% | 5.3% | ||
| Q4 24 | 8.5% | 73.2% | ||
| Q3 24 | 6.9% | 20.8% | ||
| Q2 24 | -1.9% | 17.8% | ||
| Q1 24 | -1.4% | 8.6% |
| Q4 25 | 1.9% | 10.4% | ||
| Q3 25 | 1.3% | 1.8% | ||
| Q2 25 | 1.2% | 2.2% | ||
| Q1 25 | 1.0% | 2.3% | ||
| Q4 24 | 1.9% | 9.1% | ||
| Q3 24 | 1.5% | 1.7% | ||
| Q2 24 | 3.0% | 2.4% | ||
| Q1 24 | 3.3% | 3.3% |
| Q4 25 | 2.41× | 28.39× | ||
| Q3 25 | 3.46× | 4.45× | ||
| Q2 25 | 0.81× | 0.97× | ||
| Q1 25 | 0.55× | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | 2.21× | 18.22× | ||
| Q2 24 | 0.97× | 4.29× | ||
| Q1 24 | 0.94× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
